Estimating the Cost-Effectiveness of Tumor Treating Fields (TTFields) Therapy with an Immune Checkpoint Inhibitor or Docetaxel in Metastatic Non-Small Cell Lung Cancer

Estimating the Cost-Effectiveness of Tumor Treating Fields (TTFields) Therapy with an Immune Checkpoint Inhibitor or Docetaxel in Metastatic Non-Small Cell Lung Cancer

Wesley Furnback,1 Elizabeth Wu,1 Cloe Ying Chee Koh,2 Jorge Fernando Nino de Rivera Guzman,2 Christian Kruhl,3 Rupesh Kotecha,4 Bruce CM Wang3 1Real Chemistry, New York, NY, USA; 2Novocure, Inc, Portsmouth, NH, USA; 3Novocure GmbH, Root, Switzerland; 4Department of Radiation Oncology, Miami Cancer I...

Full description

Saved in:

Bibliographic Details
Main Authors:	Furnback W, Wu E, Koh CYC, Nino de Rivera Guzman JF, Kruhl C, Kotecha R, Wang BC
Format:	Article
Language:	English
Published:	Dove Medical Press 2025-02-01
Series:	ClinicoEconomics and Outcomes Research
Subjects:	lung cancer chemotherapy immunotherapy cost-effectiveness tumor treating fields
Online Access:	https://www.dovepress.com/estimating-the-cost-effectiveness-of-tumor-treating-fields-ttfields-th-peer-reviewed-fulltext-article-CEOR
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Radiotherapy(R) Integration(I) Strategy for Small(S)-Cell Lung Cancer in Extensive(E) Stage (RISE) with up to 10 metastases- a study protocol of a randomized phase II trial
by: Łukasz Kuncman, et al.
Published: (2025-01-01)

Comparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and network meta-analysis
by: Linfeng Wang, et al.
Published: (2025-01-01)

Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study
by: Toshiaki Tsurui, et al.
Published: (2025-02-01)

Early Effects of Bronchoscopic Cryotherapy in Metastatic Non-Small Cell Lung Cancer Patients Receiving Immunotherapy: A Single-Center Prospective Study
by: Gediminas Vasiliauskas, et al.
Published: (2025-01-01)

Small cell lung cancer with EML4-ALK fusion: report of a case responding to ALK TKI and literature review
by: Mingyue Wang, et al.
Published: (2025-02-01)

Perioperative or neo/adjuvant chemoimmunotherapy versus chemotherapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis
by: Qiong Zhang, et al.
Published: (2025-01-01)

Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy
by: Meifeng Luo, et al.
Published: (2025-02-01)

Impact of thoracic radiotherapy on first‐line treatment outcomes in ES‐SCLC patients
by: Xiaoli Mu, et al.
Published: (2024-09-01)

Bibliometric insight into neoadjuvant immunotherapy in non-small cell lung cancer: trends, collaborations, and future avenues
by: Pengliang Xu, et al.
Published: (2025-02-01)

Characterization of tumor prognosis and sensitive chemotherapy drugs based on cuproptosis-related gene signature in ovarian cancer
by: Wei Tan, et al.
Published: (2025-01-01)

A Narrative Review of Prognostic Gene Signatures in Oral Squamous Cell Carcinoma Using LASSO Cox Regression
by: Nur Fatinazwa Mohd Faizal, et al.
Published: (2025-01-01)

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
by: Ichiro Yamauchi, et al.
Published: (2025-01-01)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
by: Filippo Francini, et al.
Published: (2011-01-01)

Evolution of drug therapy in patients with resectable gastric and esophageal‑gastric junction cancer
by: M. V. Sedova, et al.
Published: (2023-06-01)

Chemoimmunotherapy as induction treatment in concurrent chemoradiotherapy for patients with nasopharyngeal carcinoma stage IVa
by: Kun-Peng Wu, et al.
Published: (2025-12-01)

Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors
by: Mei Zhan, et al.
Published: (2025-01-01)

Immune Checkpoint Blockade in Melanoma – Earlier is Better?
by: Vincas Urbonas, et al.
Published: (2024-09-01)

Gut Microbiota–Tumor Microenvironment Interactions: Mechanisms and Clinical Implications for Immune Checkpoint Inhibitor Efficacy in Cancer
by: Said SS, et al.
Published: (2025-01-01)

Efficacy and safety of immune checkpoint inhibitors in patients with advanced intrahepatic cholangiocarcinoma
by: Ziting Peng, et al.
Published: (2025-02-01)

Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors
by: Yuhui Yang, et al.
Published: (2025-02-01)

Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression
by: Jianfeng Peng, et al.
Published: (2025-02-01)

A case report: interstitial pneumonia following treatment of gastric cancer with sintilimab in combination with S-1
by: Pei Zhu, et al.
Published: (2025-02-01)

Tailoring traditional Chinese medicine in cancer therapy
by: Shuiquan Li, et al.
Published: (2025-01-01)

PD(L)1 Inhibitors Plus Lenvatinib Vs Atezolizumab Plus Bevacizumab Combined With HAIC for Unresectable HCC: A Propensity Score Matching Study
by: He Z, et al.
Published: (2025-01-01)

From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy
by: Anqi Lin, et al.
Published: (2025-12-01)

FLT3 is associated with dendritic cell infiltration, tertiary lymphoid structure construction, and predict response to checkpoint inhibitors immunotherapy in solid cancers
by: Yongchang Tang, et al.
Published: (2025-01-01)

Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer
by: Nan Niu, et al.
Published: (2025-01-01)

Partial Stereotactic Ablative Radiotherapy Boost Before Conventional Radiotherapy (P‐SABR) for Large (> 5 cm) Unresectable Stage III Nonsmall Cell Lung Cancer
by: Yun Bai, et al.
Published: (2025-01-01)

MELANOMAS, SARCOMAS, AND RENAL METASTASES IN THE LIVER: HOW TO TREAT?
by: Angelica Maria LUCCHESE, et al.
Published: (2025-01-01)

Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial
by: Ying Cheng, et al.
Published: (2025-02-01)

Neoadjuvant chemotherapy combined with antiangiogenic therapy and immune checkpoint inhibitors for the treatment of locally advanced gastric cancer: a real - world retrospective cohort study
by: Zhouwei Zhan, et al.
Published: (2025-02-01)

Prognostic Impact of Adjuvant Immunotherapy in Patients With Resectable NSCLC After Neoadjuvant Chemoimmunotherapy: A Brief Report
by: Yichen Dong, MD, et al.
Published: (2025-01-01)

Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors
by: Zixi Wu, et al.
Published: (2025-12-01)

Docetaxel-Induced Stevens-Johnson Syndrome in a Patient with Metastatic Prostate Adenocarcinoma
by: Osama Diab, et al.
Published: (2019-01-01)

Initial Treatment Modalities in Patients with Newly Diagnosed Primary Lung Cancer in Japan
by: Qingqing Hu, et al.
Published: (2025-01-01)

Uterine endometrioid adenocarcinoma with pilomatrix-like differentiation: A case report and review of the literature
by: L. Rusnell, et al.
Published: (2025-02-01)

Integrated analysis of M2 macrophage-related gene prognostic model and single-cell sequence to predict immunotherapy response in lung adenocarcinoma
by: Meifang Li, et al.
Published: (2025-02-01)

Deregulated methylation and expression of PCDHGB7 in patients with non-small cell lung cancer: a novel prognostic and immunological biomarker
by: Yue Yuan, et al.
Published: (2025-01-01)

An Open‐Label Phase II Trial of Pembrolizumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Azacitidine as Second‐Line Therapy for Advanced Head and Neck Squamous Cell Cancers
by: Vinod K. Ramani, et al.
Published: (2025-01-01)

Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study
by: Ping Zhou, et al.
Published: (2024-12-01)